Lunit: AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC SEOUL, South Korea, March 26,...

Utilizing Owkin’s expansive data network and cutting-edge AI, this solution optimizes pre-screening for gBRCA mutations in breast cancer directly from digitized H&E pathology slides The solution aims to improve gBRCA...

Ibex: Our AI Algorithm to Aid Pathologists with Accurate and Reproducible HER2 and HER2-low Assessment in Breast Cancer Diagnosis TEL AVIV, Israel, Jan. 24, 2023 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer...

Rudy Hovelinck joins Pathomation as Chief Operational Officer (COO) on February 21, 2022. ANTWERP, BELGIUM (PRWEB) FEBRUARY 18, 2022 Pathomation today announced that Rudy Hovelinck will fill in the new position of Chief Operational Officer...

Big news this morning with acquisition of Definiens by MedImmune, strengthening MedImmune's focus on the discovery of novel predictive biomarkers in immune-oncology. Good news for patients and their providers. Tuesday, 4 November 2014 -...